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In the last 10 years, major advances have been made in the diagnosis and development 
of selective therapies for several blood cancers, including B-cell non-Hodgkin lymphoma 
(B-NHL), a heterogeneous group of malignancies arising from the mature B lymphocyte 
compartment. However, most of these entities remain incurable and current treatments 
are associated with variable efficacy, several adverse events, and frequent relapses. 
Thus, new diagnostic paradigms and novel therapeutic options are required to improve 
the prognosis of patients with B-NHL. With the recent deciphering of the mutational 
landscapes of B-cell disorders by high-throughput sequencing, it came out that different 
epigenetic deregulations might drive and/or promote B lymphomagenesis. Consistently, 
over the last decade, numerous epigenetic drugs (or epidrugs) have emerged in the 
clinical management of B-NHL patients. In this review, we will present an overview of the 
most relevant epidrugs tested and/or used so far for the treatment of different subtypes 
of B-NHL, from first-generation epigenetic therapies like histone acetyl transferases 
(HDACs) or DNA-methyl transferases (DNMTs) inhibitors to new agents showing selectivity 
for proteins that are mutated, translocated, and/or overexpressed in these diseases, 
including EZH2, BET, and PRMT. We will dissect the mechanisms of action of these 
epigenetic inhibitors, as well as the molecular processes underlying their lack of efficacy 
in refractory patients. This review will also provide a summary of the latest strategies being 
employed in preclinical and clinical settings, and will point out the most promising lines of 
investigation in the field.
Keywords: B-cell lymphoma, DNMT, EZH2, HDAC, PRMT inhibitor, BET bromodomain inhibitor (BETi), 
combination therapy
INTRODUCTION
Characteristics of B-Cell Non-Hodgkin Lymphoma (B-NHL)
At the origin of 4% of all cancers and more than 90% of the cases of lymphoma, B-NHLs comprise 
a heterogeneous group of lymphoid neoplasms. According to the last World Health Organization 
hematopoietic and lymphoid tumor classification, more than 40 distinct entities are categorized, 
according to a combination of morphological, immunophenotypic, genetic, and clinical 
features, having each entity its own clinical course and requiring specific treatments (Table 1) 
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(Campo  et  al., 2011; Scott and Gascoyne, 2014; Swerdlow 
et al., 2016). Originated from either mature or immature 
B cells, B-NHLs are characterized by the proliferation of 
lymphocytes, mainly in lymphoid organs and in extranodal 
tissues. Their diversity can often be traced to a particular stage 
of differentiation, from the bone marrow where the normal 
precursor B cell is originated to secondary lymphoid tissues 
where B cells undergo multiple rounds of selection before their 
differentiation into plasma cells or memory B cells. During 
these processes, the VDJ heavy chain is formed, followed by 
VJ light-chain gene rearrangement, which allows the pre-B 
cells to express intracytoplasmic μ-heavy chains. Subsequently, 
immature immunoglobulin (Ig)-positive B cells are formed. 
Within the lymph node, and in contact with a determined 
antigen, naïve B cells can mature into IgM-secreting plasma 
cells or may proliferate into primary follicles to form germinal 
center (GC) centroblasts. Upon maturation, they further 
differentiate into centrocytes, which give place to memory B 
TABLE 1 | Classification of B-cell non-Hodgkin lymphoma.
Name Cell of origin Genetic aberration Involved genes Frequency (%) References
B-ALL Hematopoietic stem cell or  
B-cell progenitor
Hyperdiploidy 
t(12;21)(p13.2;q22.1) 
t(1;19)(q23;p13.3) 
t(9;22)(q34.1;q11.2)
– 
ETV6/RUNX1 
TCF3/PBX1 
BCR/ABL1
31* 
28* 
9* 
5*
(Yeoh et al., 2002)
CLL/SLL Naïve (unmutated IGHV  
subset) or memory (mutated  
IGHV subset) B cell
del(13q14.3) 
– 
Trisomy of 12 
del(11q)
–
SF3B1 
–
ATM
54 
21 
14 
12
(Haferlach et al., 2007)
(Landau et al., 2015)
LPL Post-follicular B cell – 
del(6q) 
–
MYD88 
– 
CXCR4 
ARID1A
90 
43 
27 
17
(Hunter et al., 2014)
NMZL Post-germinal center  
marginal zone B cell
Gains of 3p 
Gains of 18q 
del(6q23)
– 
– 
TNFAIP3
24 
24 
16
(Rinaldi et al., 2011)
EMZL-MALT Post-germinal center marginal  
zone B cell
Trisomy of 3 
del(6q23) 
t(11;18)(q21;q21) 
Trisomy of 18
– 
TNFAIP3 
BIRC3/MALT1 
–
31 
30 
13 
11
(Streubel et al., 2004)
(Rinaldi et al., 2011)
SMZL Marginal zone B cell with or  
without antigen exposure
del(7q) 
Gains of 3q 
del(17p13) or mutation
–
–
– 
TP53 
KLF2
26 
20 
16 
12
(Rinaldi et al., 2011)
(Parry et al., 2015)
HCL Late activated memory B cell –
–
BRAF 
MAP2K1
100 
48
(Tiacci et al., 2011)
(Waterfall et al., 2013)
FL Germinal center B cell t(14;18)(q32;q21)
–
– 
–
IGH/BCL2 
KMT2D 
CREBBP 
TNFRSF14
89 
82 
64 
35
(Horsman et al., 1995)
(Okosun et al., 2014)
MCL Peripheral B cell of the inner  
mantle zone
t(11;14)(q13;q32) 
Gain of 3q26 
del(11q) or mutation 
del(17p13) or mutation
IGH/CCND1 
– 
ATM 
CCND1 
TP53
57 
49 
41 
34 
27
(Beà et al., 1999) 
(Beà et al., 2013)
DLBCL-GCB Peripheral mature B cell of  
germinal center origin
– 
del(1p36) or mutation 
Gains of 2p16 
t(18q21)
KMT2D 
TNFRSF14 
REL 
BCL2
46 
38 
30 
28
(Dubois et al., 2016)
(Scholtysik et al., 
2015)(Roulland et al., 
2018)
DLBCL-ABC Peripheral mature B cell of  
germinal center exit or post- 
germinal center
del(9p21) 
del(6q21) or mutation 
–
–
CDKN2A 
PRDM1 
KMT2D 
MYD88
47 
41 
41 
28
(Scholtysik et al., 
2015)(Dubois et al., 
2016)
BL Germinal center B cell t(8;14)(q24;q32) 
–Other t(8q24)
MYC/IGH 
ID3 
TCF3 
MYC
77 
58 
29 
8–15
(Toujani et al., 2009)
(Schmitz et al., 2012)
*Frequency in pediatric cases. B-ALL, B-cell acute lymphocytic leukemia; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma;  
LPL, lymphoplasmacytic lymphoma; NMZL, nodal marginal zone lymphoma; EMZL-MALT, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue; 
SMZL, splenic marginal zone lymphoma; HCL, hairy cell leukemia; FL, follicular lymphoma; MCL, mantle cell lymphoma; DLBCL-GCB, diffuse large B-cell lymphoma of 
germinal center B-cell subtype; DLBCL-ABC, diffuse large B-cell lymphoma of activated B-cell subtype; BL, Burkitt lymphoma.
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cells or plasma cells. Within the GC, somatic hypermutation in 
the Ig heavy or light chain variable region (IGHV or IGHL) genes 
leads to increased antigen affinity.
Although tightly regulated, the B-cell differentiation 
process and especially the antibody diversification phase 
can be accompanied by inherited events that may favor 
lymphomagenesis, such as chromosomal translocations, 
oncogene activation, and/or inactivating mutations in tumor 
suppressor genes. Infection by determined viruses, such as the 
Epstein–Barr virus, has also been involved in lymphomagenesis. 
The malignant counterparts of the early B-cell differentiation 
steps account for B lymphoblastic lymphomas, which harbor 
high similarity with B progenitor cells. On the other hand, 
mantle cell lymphomas (MCLs) and a subset of chronic 
lymphocytic leukemia (CLL) with unmutated IGHV are 
thought to derive from naive B cells and pre-GC mature B 
cells expressing the CD5 surface marker. Other GC-originated 
lymphomas, including follicular lymphoma (FL), Burkitt’s 
lymphoma (BL), a subset of diffuse large B-cell lymphoma 
(DLBCL), and Hodgkin’s lymphoma (HL), present mutations 
in IGHV gene. Additional entities, including marginal zone 
lymphoma (MZL), lymphoplasmacytic lymphoma, CLL with 
somatic IGHV mutation, another subset of DLBCL, and 
multiple myeloma (MM) correspond to post-GC cells. Each 
lymphoma subtype retains key features of their cell of origin 
as judged by the similarity of immunophenotype, histological 
appearance, and gene expression profiles (Seifert et al., 2013) 
(Table 1). The putative normal B-cell counterpart of each 
B-cell lymphoma is summarized in Figure 1.
In the last decade, loads of evidences have suggested an 
association between the frequent alterations in chromatin state 
and epigenetic regulators observed in B-NHL patients, and 
disease formation and progression.
Altered Chromatin-Modifying Enzymes  
in B-NHL
Contrary to the general belief that only accumulations of 
DNA mutations might lead directly to the development of 
tumorigenic processes, it has been progressively reported 
a growing subset of epigenetic alterations lying at the basis 
of many malignancies, including those occurring in lymph 
nodes. Interestingly, in B-cell lymphomas, certain somatic 
mutations in chromatin-modifying enzymes account for 
several epigenetic alterations, suggesting that an aberrant 
epigenetic landscape in B-NHL may be a consequence of 
genetic alterations associated with a particular lymphoma 
subtype. For instance, deleterious and/or loss of function 
mutations in the histone acetyltransferase CREB binding 
protein (CREBBP) or the E1A binding protein 300 (EP330) 
have been reported in about 40% of DLBCL and FL patients 
as well as in other lymphoma subtypes (Morin et al., 2011; 
Pasqualucci et al., 2011b). Recurrent point mutations in the 
histone acetyl transferase (HAT) recruiting gene myocyte 
enhancer binding factor 2B (MEF2B) have been also described 
in 15% of FL and 13% of DLBCL patients with germinal center 
B cell (DLBCL-GCB) subtype (Morin et al., 2011). Although 
no mutations have been reported in the genes coding for 
histone deacetylases (HDACs), several members of this 
family like HDAC1, 2, and 6 can be overexpressed in DLBCL, 
in association with a decrease in the DNA accessibility to the 
transcription machinery (Marquard et al., 2009).
In addition to mutations in chromatin‐regulatory proteins, 
epigenetic modifications at chromatin level are also commonly 
observed in B-NHL as a result of profound changes in DNA 
methylation patterns. Indeed, while hypo- and hyper-DNA 
methylation status have been linked to the pathogenesis of 
several cancer subtypes, somatic mutations in epigenetic 
genes codifying for DNA methylation regulators have been 
particularly well associated to a repressed chromatin state and 
to malignant processes in B-NHL (Esteller et al., 2001; Hassler 
et al., 2013). Among the main reported alterations, activating 
mutations in enhancer of zeste homolog 2 (EZH2), a histone 
methyltransferase (HMT) gene, were found in 22% of DLBCL-
GCB patients and 7% of FL patients (Morin et al., 2010). Further 
loss‐of‐function mutations were observed in the histone-Lysine 
N-Methyltransferase 2D (MLL2/KMT2D) gene in about 90% of 
FL and 30% of DLBCL patients (Morin et al., 2011; Pasqualucci 
et al., 2011b; Lohr et al., 2012). Concretely, MLL2 presents a 
defective SET domain when mutated by either truncation or 
frameshift mutations, leading to a reduced H3K4 methylation 
activity (Shilatifard, 2008; Morin et al., 2011; Pasqualucci et al., 
2011b; Lohr et al., 2012).
Hence, B-NHL occurrence as a result of disruption in 
epigenetic mechanisms has generated a strong rationale to 
target epigenetic and chromatin regulators for drug discovery 
attempts. To address these alterations, several Food and Drug 
Administration (FDA)–approved epigenetic-modulating 
agents, whose clinical use has been mainly restrained so far 
to other hematological malignancies (Popovic et al., 2013), 
are now being made available for their evaluation in B-NHL. 
FIGURE 1 | Major B-cell non-Hodgkin lymphoma subtypes arise from 
different cell of origin within the lymph node. Mantle cell lymphomas 
(MCL) arise from naive B cells or germinal center (GC) B cells found within 
the mantle zone. Marginal zone lymphomas initiate from naive B cells or 
GCB that have entered the marginal zone. GCB are the origin of follicular 
lymphomas (FL), Burkitt lymphoma (BL), and diffuse large B-cell lymphomas 
(DLBCL) when still in the germinal center. This last DLBCL appears to also 
form GCB within the marginal zone or from fully developed memory B cells.
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These agents include the HDAC inhibitors romidepsin (FK228, 
depsipeptide), vorinostat (suberanilohydroxamic acid, SAHA), 
panobinostat (LBH589), and belinostat (PXD101); the DNA 
methyltransferase (DNMT) inhibitors (hypomethylating 
agents, HMAs) azacitidine (5-azacytidine) and decitabine 
(5-aza-2′-deoxycytidine); and the isocitrate dehydrogenase 
(IDH) inhibitors enasidenib (AG-221) and ivosidenib (AG-
120) (Table 2).
TARGETING wRITER EPIGENETIC 
ENZYMES
DNMT Inhibitors
DNA methylation is responsible for the control of gene expression 
and for maintaining genomic stability during embryogenesis and 
tissue differentiation (Meissner, 2010). This process is clonally 
inherited and preserved in daughter cells, and occurs through 
the inclusion of a methyl group at cytosine residues in CpG 
dinucleotides (Figure 2). It is carried out by the DNMTs, namely 
DNMT1 which primarily mediates maintenance methylation 
during cell division, and DNMT3A and 3B that regulate de novo 
DNA methylation (Belinsky et al., 2003; Hermann et al., 2004). 
DNA methylation is thought to have a significant role in the 
regulation of lymphoid compartment, as it has been demonstrated 
that differential recruitment of DNMT1, DNMT3A, and 
DNMT3B and consequent specific DNA methylation patterns 
are determined at early stages during lymphopoiesis and B-cell 
activation (Shaknovich et al., 2011; Lai et al., 2013).
While on the one hand, DNA methylation is essential for 
cell homeostasis, on the other hand, disturbance in methylation 
pattern have been widely described in cancer. Changes in CpG 
methylation are indeed commonly associated with malignant 
transformation and tumor progression (Berdasco and Esteller, 
2010). In addition, accumulating evidences suggest that 
aberrant epigenetic regulation, including DNA methylation, 
exerts an important role in regulating each cancer’s hallmarks 
(Flavahan et al., 2017). Illustrating this relationship in B-NHL, 
Shaknovich and collaborators demonstrated the relevance of 
DNA methylation in defining the molecular DLBCL subtypes 
(Shaknovich et al., 2010). It was further proposed that DNMT1 
and DNMT 3B overexpression may play a role in malignant 
progression of these tumors (Amara et al., 2010) and also in BL 
neoplasm (Robaina et al., 2015). In line with this, the disruption 
of DNA methylation pattern is correlated with disease severity 
and patient survival in DLBCL and FL (De et al., 2013).
Considering that the majority of cancers, including B-NHL, 
harbor an altered DNA methylation pattern, and also taking 
into account the reversibility of this alteration, the idea to 
modulate the methylation machinery to restore a “normal” 
DNA methylation state has attracted great attention in cancer 
treatment (Azad et al., 2013). The first two DNA methylation 
epigenetic compounds (DNMTi) ratified by the FDA and the 
European Medicines Agency for cancer treatment, azacitidine 
and decitabine (Jones et al., 2016), were initially described as 
promising chemotherapeutic agents against myelodysplastic 
syndrome (MDS) and acute myeloid leukemia (AML), although 
with moderate efficacy and high toxicity (Li et al., 1970; Vogler 
et al., 1976). In further trials, low-dose decitabine and azacitidine 
demonstrated to be effective in these patients, improving both 
the response and the overall survival (OS), leading to their 
further approval (Table 2 and Figure 3) (Silverman et al., 2002; 
Fenaux et al., 2009; Lübbert et al., 2016). In B-NHL patients, 
two phase I studies using decitabine have been completed so far, 
but the response to therapy and the effect on DNA methylation 
were moderate (Stewart et al., 2009; Blum et al., 2010). Currently, 
azacitidine and decitabine are being evaluated alone or in 
combination in approximately 10 active clinical trials involving 
relapsed/refractory R/R B-NHL patients (Table 3). Considering 
the preliminary data of these trials, it seems premature to 
conclude that DNMTis can be used as monotherapy in B-NHL.
Although the mechanism of action of DNMTi is not well 
understood, the activity of decitabine and azacitidine is known 
to involve their incorporation into the DNA of proliferating cells, 
followed by irreversible inhibition of DNMT1 enzymatic activity 
and the addressing of this latest to proteasomal degradation 
TABLE 2 | FDA-approved epigenetic drugs for hematological malignancies.
Agent Target Indication Year of approval Current development
Azacitidine DNMT MDS 
CMML 
AML
2004
Decitabine DNMT MDS 
AML
2006 Atherosclerosis
Vorinostat HDAC CTCL 2006
Romidepsin HDAC CTCL 
PTCL
2009 
2011
HIVAutism
Belinostat HDAC PTCL 2014 Ovarian cancer
CTCL
Panobinostat HDAC MM 2015 CML 
MDS 
Breast cancer 
Prostate cancer
DNMT, DNA methyltransferase; HDAC, histone deacetylase; MDS, myelodysplastic syndrome; CMML, chronic myelomonocytic leukemia; AML, acute myeloid 
leukemia; CTCL, cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma; MM, multiple myeloma.
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(Ghoshal et al., 2005; Juttermann et al., 2006). Accordingly, 
two main molecular effects have been described for DNMTi 
inhibitors: (1) a global demethylation of gene promoters (mainly 
tumor suppressor genes) and (2) the activation of immune 
system and the triggering of an anti-tumor immune response 
(Groudine et al., 1981; Almstedt et al., 2010; Goodyear et al., 2010; 
Chiappinelli et al., 2015;). As an illustration, in DLBCL it has 
been described that decitabine can reverse DNA methylation and 
restore expression of important cancer-related pathways in vitro 
and in vivo (Li et al., 2002; Clozel et al., 2013), although in other 
studies a less drastic and transient effect was observed (Karpf, 
2004; McGarvey et al., 2006; Egger et al., 2007). Furthermore, 
DNMT inhibition is also linked to the demethylation of gene 
bodies, leading to oncogene downregulation (Wong et al., 2013; 
Yang et al., 2014).
Several new DNMTis have been developed in the last decade 
with potential activity in hematological malignancies. Among 
them, thioguanine (2-amino-1,7-dihydro-6H-purine-6-thione 
(6-tG)) has been approved by FDA to treat AML patients (Munshi 
et al., 2014). Its mechanism of action involves its incorporation 
into DNA, decrease in DNMT activity and DNA methylation, 
blockade of DNA and RNA synthesis, and ultimately cell death 
(Hogarth et al., 2008; Yuan et al., 2011; Flesner et al., 2014). 
Recently described as an experimental DNMTi, 5-fluoro-2′-
deoxycytidine (FdCyd) is currently undergoing a phase I/II 
clinical trial in combination with other drugs (Kinders et al., 
2011; Newman et al., 2015). Its mechanism of action involves the 
ability to block DNMT-dependent DNA methylation (Jones and 
Taylor, 1980; Beumer et al., 2008). 5,6-Dihydro-5-azacytidine is 
a reduced, hydrolytically stable form of 5-azacytidine nucleoside 
(Beisler et al., 1979). The mechanism of action is very similar 
to that described for azacytidine, with the advantage of a lower 
toxicity (Avramis et al., 1989). However, its evaluation in clinical 
settings revealed a reduced response rate and the rise of significant 
adverse effects (Samuels et al., 1998). Zebularine is another 
DNMTi, which has been previously described as tumor-selective 
FIGURE 2 | Mechanisms of action of common epigenetic enzymes. Histone methylation is regulated by histone methyltransferases (HMTs), such as the EZH2 
subunit of polycomb repressive complex 2 (PRC2), and histone demethylases (HDMTs). DNA methylation is established by DNA methyltransferases (DNMTs) and 
reversed by several enzymes like TET hydroxymethylases. Demethylation of both histones and DNA is inhibited by 2-hydroxyglutarate (2-HG), produced from 
α-ketoglutarate (α-KG) by mutant forms of IDH1/2 enzymes (mIDH). Histone acetylation is regulated by histone acetyltransferases (HATs) and histone deacetylases 
(HDACs). Bromodomain-containing proteins, such as CREB-binding protein (CBP), BET, or the BRD9 subunit of the SWI/SNF complex, bind to acetylated residues 
of histones.
FIGURE 3 | Timeline of FDA approvals of epigenetic-modulating therapies in 
hematological cancers. Source: https://www.accessdata.fda.gov/scripts/cder/daf/
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inhibitor of DNMTs (Cheng et al., 2004). Although there are a lot 
of evidences, both in vitro and in vivo, indicating the potential of 
zebularine as a demethylating agent in a wide range of tumors 
(Agrawal et al., 2018), its poor bioavailability has prevented its 
introduction into clinical trials (Ben-Kasus et al., 2005). More 
recently, 4′-thio-2′-deoxycytidine (TdCyd) and its 5-aza analog, 
5-aza-TdCyd, have been reported to downregulate DNMT1 and 
to exhibit anti-tumor activity in vitro and in human leukemia 
and lung cancer xenografts (Thottassery et al., 2014). Among 
these last molecules, TdCyd has already entered into phase I 
clinical evaluation (NCT02423057 and NCT03366116). Further 
molecules were developed with superior anti-tumoral efficacy 
and included guadecitabine (SGI-110), a second-generation 
DNMTi that harbors an improved DNA methylation inhibition 
in solid tumors both in vitro and in vivo (Chuang et al., 2010; 
Srivastava et al., 2015). A phase I clinical trial has provided 
promising results in patients with MDS and AML (Issa et al., 
2015). Fluorocyclopentenylcytosine (RX-3117) is a cytidine 
analog that presents an anti-tumor activity in a large set of tumor 
cells and in vivo. Its mechanism of action is associated with an 
inhibition of DNMT1 (Choi et al., 2012). This agent is being 
evaluated in a phase II study with R/R pancreatic or advanced 
bladder cancer (NCT02030067).
EZH2 Inhibitors
EZH2 constitutes the catalytic subunit of the polycomb 
repressive complex 2 (PRC2). Its structure is composed by a 
SET domain, typical in chromatin-associated regulators of gene 
expression (Xiao et al., 2003). It catalyzes histone H3 lysine 27 
tri-methylation (H3K27me3) and the subsequent formation 
of heterochromatic regions and downregulation of the nearby 
genes (Bracken and Helin, 2009; Ferrari et al., 2014) (Figure 2). 
In B lymphocytes, EZH2 becomes expressed and inhibited in a 
cyclic manner. First, in pre-B lymphocytes, induction of EZH2 
expression is required for an optimal V(D)J recombination. Later 
on, during the migration to lymphoid tissues, it is downregulated 
until the GC reaction occurs, after which it becomes re-expressed 
to allow the silencing of the anti-proliferative genes cyclin-
dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent 
kinase inhibitor 1A (CDKN1A1) and the pro-differentiation genes 
interferon regulatory factor 4 (IRF4) and PR domain zinc finger 
protein 1 (PRDM1/BLIMP1) during the somatic hypermutation 
and isotype switch processes. Finally, EZH2 becomes repressed 
when mature B cells leave the GC (Velichutina et al., 2010; 
Béguelin et al., 2013). Gain-of-function mutations in EZH2 
have been reported in several solid tumors and hematological 
cancers. The consequence of those mutations in GC lymphocytes 
is the irreversible silencing of certain cell cycle checkpoint and 
plasma cell differentiation genes (Béguelin et al., 2013). The main 
gain-of-function mutation identified in DLBCL and FL patients 
includes a tyrosine deletion (Y641) at the EZH2 SET domain that 
increases the levels of H3K27me3, promoting a repressed state of 
cell differentiation and the repression of tumor suppressor genes 
(Morin et al., 2010; McCabe et al., 2012a). Similar effects have 
been described as a consequence of the A677G mutation in EZH2, 
which has been characterized in multiple human lymphoma 
cell lines. A change in the substrate preferences accounts for 
the aberrant H3K27me3 levels observed in cells bearing EZH2 
mutant forms. Indeed, wt EZH2 displays preference for less 
methylated substrates whereas Y641 and A667G mutants prefer 
either substrates with higher methylation levels or show equal 
TABLE 3 | Selected examples of epigenetic drugs under clinical evaluation in B-NHL patients as single agents.
Epigenetic drug class Drug Diseases Sponsor Trial identifier
HDAC inhibitor Vorinostat FL, indolent B-NHL, MCL Merck Sharp & Dohme Corp. NCT00875056
Chidamide (Epidaza) R/R B-NHL Sun Yat-sen University NCT03245905
Abexinostat R/R FL Xynomic Pharmaceuticals, Inc. NCT03934567
Mocetinostat (MGCD0103) DLBCL, FL Memorial Sloan Kettering Cancer Center and 
MethylGene Inc.
NCT02282358
Ricolinostat(ACY-1215) R/R NHL Acetylon Pharmaceuticals Inc. and Columbia 
University
NCT02091063
Panobinostat CLL Peter MacCallum Cancer Centre, Australia NCT01658241
CDX101 Advanced lymphomas Cancer Research UK and Oxford  
University Hospitals
NCT01977638
IDH1 inhibitor Ivosidenib(AG-120) Advanced hematologic malignancies 
with an IDH1 mutation
Agios Pharmaceuticals, Inc. NCT02074839
BET bromodomaininhibitor CPI-0610 Progressive lymphomas Constellation Pharmaceuticals NCT01949883
BMS-986158 Lymphomas Dana-Farber Cancer Institute NCT03936465
Molibresib (GSK525762) NHL GlaxoSmithKline NCT01943851
EZH1/2 inhibitor DS-3201b R/R B-NHL Daiichi Sankyo Co., Ltd. NCT02732275
CPI-1205 Progressive B-cell lymphomas Constellation Pharmaceuticals NCT02395601
Tazemetostat R/R B-NHL Eisai Co., Ltd. NCT03009344
Tazemetostat R/R NHL with EZH2 gene mutations National Cancer Institute (NCI) NCT03213665
PRMT inhibitor JNJ-64619178 R/R B-NHL Janssen Research & Development, LLC NCT03573310
GSK3326595 MDS, AML GlaxoSmithKline NCT03614728
GSK3368715 DLBCL GlaxoSmithKline NCT03666988
DNMT inhibitor Decitabine R/R DLBCL Mingzhi Zhang, Zhengzhou University NCT03579082
EED inhibitor MAK683 Advanced DLBCL Novartis Pharmaceuticals NCT02900651
EED, embryonic ectoderm development. Source: https://clinicaltrials.gov/.
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affinity for all three substrates (H3K73me0, me1, and me2) 
(McCabe et  al., 2012a). Interestingly, these gain-of-function 
EZH2 variants expressed in GC B-cell lymphomas seem to 
synergize with BCL2 deregulation, favoring the progression of 
these malignancies (Béguelin et al., 2013). On the other hand, 
overexpression of wt EZH2 has been also reported in B-NHL 
(Van Kemenade et al., 2001; Visser and Gunster, 2001), with a 
positive correlation being observed between EZH2 transcript 
levels, tumor aggressiveness, and disease prognosis (Abd Al 
Kader et al., 2013). Taking into account these considerations, it 
looks reasonable that inhibiting EZH2 activity could result in a 
potential therapeutic strategy to treat B-NHL.
In this context, many efforts directed to develop highly 
selective EZH2 inhibitors have been made in the last decade. 
EZH2 activity was initially targeted by means of the carbocyclic 
adenosine analog 3-deazaneplanocin A (DZNep), an inhibitor of 
S-adenosylhomocysteine hydrolase. DZNep promotes a global 
increase in the levels of 5-adensylhomocystein and a further 
inhibition in the activity of many methyltransferases, including 
EZH2. Nevertheless, due to its mechanism of action, it resulted to 
be too unspecific as many other methyltransferases were similarly 
affected. In 2012, a small chemical compound named El1 with a 
good capacity to inhibit the Y641 mutant and wt EZH2 form 
was evaluated for the treatment of DLBCL. This compound was 
designed as a competitive inhibitor of the EZH2 methyl group 
donor S-adenosyl--methionine (SAM). Unlike DZNep, El1 showed 
a 10,000-fold selectivity for EZH2 over other HMTs and a 90-fold 
selectivity over EZH1 methyltransferase. This compound promoted 
a global decrease in methyl donor availability, leading to a lower 
global levels of H3K27me3 (Qi et al., 2012). Other subsequent 
compounds directed specifically against EZH2 are the dual 
EZH2/1 inhibitors UNC1999, with a potent capacity to suppress 
H3K27me3 and H3K27me2 levels and to inhibit proliferation of 
mixed lineage leukemia (MLL)-rearranged cells, and the OR-S1 
and OR-S2 inhibitors, which were assessed for the treatment of 
DLBCL, AML, and MM (Konze et al., 2013; Honma et al., 2017). 
Later on, EPZ0005687 and GSK126, two selective and SAM-
competitive EZH2 inhibitors with a higher inhibitory capacity 
for the mutant EZH2 form, were developed and tested in DLBCL 
and FL (McCabe et al., 2012b; Knutson et al., 2014). In 2014, 
GSK126 entered into phase I clinical trials with B-NHL and MM 
patients (NCT02082977) (Zeng et al., 2016; Yap et al., 2018), but 
unfortunately that study had to be discontinued as a consequence 
of insufficient therapeutic activity, evidencing the need to keep 
working in the improvement of those inhibitors. Also in 2014, CPI-
360 and its more potent and stable analog, CPI-169, were reported 
to be effective EZH2 inhibitors for the treatment of several B-NHL 
subtypes (Vaswani et al., 2016). An improved version of these latest, 
CPI-1205, showed a higher oral bioavailability and was first tested 
in preclinical studies with xenograft mouse models generated from 
human B-NHL cell lines and further challenged in phase I trials for 
the treatment of DLBCL (NCT02395601).
Valemetostat (DS-3201) is another potent wild-type (wt) 
and mutant EZH1/2 inhibitor that demonstrated a strong anti-
proliferative effect against NHL, DLBCL, and T-cell lymphoma 
(Maruyama et al., 2017). Currently, tazemetostat (EPZ‐6438), 
another SAM competitive inhibitor with a high affinity for the wt 
and the mutant EZH2 forms, is being evaluated in clinical studies 
to treat R/R B-NHL and MM patients (NCT03456726) (Knutson 
et al., 2014; Gulati et al., 2018), reaching an overall response rate 
of 38% in a phase I clinical trial (Italiano et al., 2018).
Despite first promising results, single-agent treatment with 
EZH2 inhibitors is in general slightly effective in aggressive 
lymphomas. Among the possible mechanism(s) of resistance, 
overactivation of the phosphatidylinositol 3-kinase (PI3K) and 
mitogen-activated protein kinase (MAPK) pathways has been 
identified in GSK126-resistant DLBCL cells (Bisserier and 
Wajapeyee, 2018). Thus, it looks reasonable to prioritize the 
discovery of new drug combination associating EZH2 inhibitors 
with other compounds targeting key signaling pathways in order 
to prevent and/or overcome the occurrence of EZH2i resistance 
in lymphoid neoplasm with mutated EZH2.
PRMT Inhibitors
A conserved biological mechanism within all eukaryotic 
organisms, from yeast to higher mammals, is arginine 
methylation (Migliori et al., 2010). This post-translational 
modification is mediated by N-arginine methyltransferases 
(PRMTs), which catalyze the transfer of a methyl group, from 
SAM to the omega nitrogens found in terminus guanidine 
group of an arginine residue of the side chain. This transfer 
may occur in one or both nitrogens (Bedford and Clarke, 
2009). Among the nine different members of the PRMT family 
(Schubert et al., 2003), PRMT1 is the major enzyme responsible 
for arginine methylation followed by PRMT5, according to 
the observation that PRMT1 and PRMT5 knockout mice die 
at an early stage during development whereas mice lacking 
any of the other seven PRMTs are fully viable (Hadjikyriacou 
et al., 2015). Protein modifications performed by PRMTs 
are traditionally related to important genetic processes such 
as DNA repair and gene transcription, among others. More 
recently, PRMT functions have been linked to carcinogenesis 
and metastasis, giving to these enzymes the status of potent 
therapeutic targets in a variety of cancers where they are 
overexpressed, including colon, breast, prostate, and lung 
cancers, neuroblastomas, leukemias, and B-cell lymphoma 
(Yoshimatsu et al., 2011).
Within this family, upregulation of PMRT1 and PRMT5 
has been widely associated with hematological malignancies 
(Greenblatt et al., 2016; Smith et al., 2018). In particular, the 
expression and function of PMRT5 have been extensively 
examined during lymphomagenesis, as this enzyme is highly 
expressed in primary samples and cell lines from different 
leukemia and lymphoma subtypes, where it promotes the 
repression of tumor suppressors such as the retinoblastoma 
proteins. In these models, experimental studies have 
suggested that PRMT5 upregulation may be caused by 
overexpression of MYC and NOTCH oncogenes (Wang et al., 
2008). In transformed DLBCL, the S-methyl-5’-thioadenosine 
phosphorylase (MTAP) gene encoding for a critical methionine 
metabolism enzyme is deleted due to its proximity to the tumor 
suppressor gene CDKN2A (Dreyling et al., 1998), and this 
phenomenon sensitizes cancer cells to PRMT5 inactivation 
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(Marjon et al., 2016). A remarkable interplay has also been 
described between PRMT5 and the B cell lymphoma 6 (BCL6) 
oncogene during the lymphomagenesis in the GC (Lu et al., 
2018), suggesting that pharmacological inhibition of arginine 
methylation could be of special interest in BCL6-driven 
lymphoma. Regarding PRMT1, an interesting interaction 
exists between this enzyme and EZH2 in DLBCL-GCB 
tumors. Indeed, recent works have reported an increase in 
PRMT1-related histone arginine methylation in DLBCL-GCB 
cells resistant to EZH2 inhibition, in association with BCL-2 
overexpression and modulation of the B-cell receptor (BCR) 
downstream signaling, supporting the rational association 
of EZH2 and PRMT1 inhibitors in DLBCL patient samples 
(Goverdhan et al., 2017).
Among the multiple functional inhibitors that have been 
developed to target the different members of the family, 
PRMT1 and PRMT5 small molecule inhibitors have already 
shown great potential against B-NHL, either alone or upon 
their combination with other agents. As an illustration, 
promising results have been obtained with the specific 
PRMT5 inhibitor EPZ015666 (GSK3235025) when used as 
single agent in in vitro and in vivo models of MCL (Chan-
Penebre et al., 2015).
TARGETING ERASER EPIGENETIC 
ENZYMES: HDAC INHIBITORS
By favoring an open chromatin state, histone acetylation allows 
numerous transcription factors to bind DNA and to activate 
gene expression. At the same time, acetylated histones increase 
DNA accessibility to transcriptional activators and counteract 
the function of transcriptional repressors (McClure et al., 2018). 
Acetylation of histones and non-histone proteins is regulated 
through a correct balance between HAT and HDAC activities. 
Among these enzymes, the most advanced subfamily is human 
HDACs, which have been classified into four classes according to 
their sequence homology, activity, and subcellular localization. 
HDACs 1, 2, 3, and 8 constitute class I. HDAC 4, 5, 6, 7, 9, and 
10 belong to class II. Class III includes sirtuin 1 (SIRT1) and 
sirtuin 7 (SIRT7), two NAD-dependent structurally unrelated 
protein deacetylases (Minucci and Pelicci, 2006). Finally, class 
IV is represented by HDAC11. In contrast to class II HDACs 
which show a heterogeneous expression pattern, class I HDACs 
are found at particularly high levels in lymphoid cell lines and 
primary tumors, suggesting a predominant role of these latest in 
lymphomagenesis. Accordingly, the design of HDAC inhibitors 
(HDACis) in lymphoid malignancies has been mainly centered 
on this latest group of enzymes (Gloghini et al., 2009).
Several structurally distinct classes of HDACis have been 
developed. These molecules can be divided into five chemical 
groups: hydroxamic acids, cyclic peptides, electrophilic ketones, 
short-chain fatty acids, and benzamides. Pan-HDACis have 
the capacity to inhibit almost all HDACs with the exception of 
class III HDACs and include the hydroxamic acid derivatives 
vorinostat, givinostat (ITF2357), abexinostat, panobinostat, 
belinostat, and trichostatin A, the carboxylate sodium butyrate, 
and the cyclic peptide trapoxin (Bradner et al., 2010; Di Costanzo 
et al., 2014). Taking into account that HDACs can also modulate 
the function of several non-histone proteins regulating a number 
of physiological processes (Lane and Chabner, 2009), and that 
HDACs can simultaneously exert pro- and anti-leukemic 
activities (Heideman et al., 2013; Santoro et al., 2013), blocking 
individual HDACs with isotype-selective inhibitors specific 
for one or two classes of HDACs might represent a strategy of 
choice for the treatment of lymphoid tumors. In line with this, 
the isotype-selective HDACis include the benzamides entinostat 
(MS-275, SNDX-275) and mocetinostat (MGCD0103) (Fournel 
et al., 2008; Vannini et al., 2004), the hydroxamic acid derivative 
rocilinostat (ACY-1215) (Santo et al., 2012), and the cyclic 
peptide romidepsin, which show preference for HDAC1-6-8, 
HDAC6, and HDAC1-2, respectively (Lemoine and Younes, 
2010). Several HDACis like vorinostat, mocetinostat, and 
entinostat can be administered orally; conversely, other agents 
like romidepsin are given intravenously (Batlevi et al., 2016; 
Mann et al., 2007; Younes et al., 2011; Holkova et al., 2017). By 
inhibiting the catalytic activity of their target HDAC(s), these 
compounds impair the formation of HDAC–substrate complexes, 
thus altering the transcriptomic pattern of the malignant cells as 
well as the activity of non‐histone proteins, ultimately leading to 
growth arrest, differentiation, and induction of apoptosis (Qiu 
et al., 2000). Of importance, when compared to their malignant 
counterparts, healthy tissues are generally unaffected by HDACis 
(Mai et al., 2005).
A number of preclinical studies have highlighted a role 
for HDACi therapy in a range of B-cell lymphoma, including 
DLBCL, HL, and BL, either alone or in combination with 
other epidrugs such as HMAs, with small molecule agents or 
with standard chemotherapeutics (Buglio et al., 2008; Kretzner 
et al., 2011; Kewitz et al., 2012; Ageberg et al., 2013; Klein et al., 
2013; Rozati et al., 2016; Garrido Castro et al., 2018). Among 
these studies, the weak HDACi valproic acid was shown to 
overcome DLBCL cell resistance to the standard R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vincristine, 
prednisone) chemotherapeutic regimen (Ageberg et al., 2013). In 
preclinical models of DLBCL and MCL, panobinostat, belinostat, 
depsipeptide, and vorinostat were shown to evoke tumor growth 
arrest, differentiation, and/or apoptosis in vitro and/or in vivo, 
mediated by the accumulation of DNA damage upon PARP 
trapping (Valdez et al., 2018), G1 cell cycle arrest consequent 
to an increase in the expression of the cyclin-dependent kinase 
inhibitor p21, acetylation of histone H3 (Xue et al., 2016), or 
transcriptional activation of the BCL-2 family proapoptotic 
members BIM, BMF, and NOXA (Kalac et al., 2011; Xargay-
Torrent et al., 2011).
Based on these preclinical studies, several HDACis have 
entered clinical trials under different modalities (monotherapies 
or in combination). Many of these trials have been conducted 
in DLBCLs, FLs, and HLs using HDACis, either alone or in 
combinatorial therapies (Watanabe et al., 2010; Stathis et al., 
2011; Younes et al., 2012; Oki et al., 2013; Ogura et al., 2014; 
Chen et al., 2015; Morschhauser et al., 2015) (Table 2 and 
Figure 3). As monotherapy, HDACis have shown a wide range 
of response in lymphoma patients, varying from complete 
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remissions (CRs) to no response. In the absence of biomarkers 
for prediction of clinical outcome, the molecular mechanisms of 
resistance are poorly understood. Vorinostat was the first proved 
in relapsed B-NHL patients, including FL, MZL, and MCL. In 
a phase II study including relapsed FL, non-FL indolent NHL 
and MCL patients, oral vorinostat showed low levels as a single 
agent, with the exception of FL, in which an overall response rate 
(ORR) of 47–49% (referring to the proportion of patients with 
tumor size reduction of a predefined amount and for a minimum 
time period) and a CR rate of 23% was observed (Kirschbaum 
et al., 2011; Ogura et al., 2014). This agent was also tolerated, but 
displayed limited activity in another phase II trial against R/R 
DLBCL, with only 1/18 patients presenting complete response 
(Crump et al., 2008).
With the pan-HDACis abexinostat and quisinostat, or the 
class-specific mocetinostat and entinostat, the response rates 
were quite variable (from 12% to 56%), and mostly dependent 
on the drug and on the lymphoma subtype. The most robust 
responses were obtained with abexinostat in FL patients (56% 
ORR). This latest drug showed a unique pharmacokinetic profile 
and an optimized oral dosing schedule that allowed for a superior 
anti-tumoral activity. In a recent phase II study with patients 
with R/R B-NHL or CLL, among the evaluable patients the ORR 
was 28%, with highest responses observed in FL patients (ORR 
56%) and DLBCL (ORR 31%) (Ribrag et al., 2017). A phase II 
clinical trial with mocetinostat in patients with R/R DLBCL and 
FL showed promising results (Batlevi et al., 2017), whereas for 
entinostat only one B-NHL patient has been included in phase II 
trial; therefore, no conclusion can be made on its efficacy in this 
subgroup of patients (Kummar et al., 2007).
Similar to DNMTis, the effectiveness of the first-generation 
HDACis carries significant toxicity and is limited to 
hematopoietic malignancies, which makes them challenging 
to combine (Suraweera et al., 2018). It is believed that part of 
this toxicity may be related to the capacity of HDACis to alter 
directly the function of many non-histone proteins. Toxicity 
may also be due to widespread activity across HDAC isoforms; 
therefore, the focus of second-generation HDACi discovery 
was to enhance the discrimination over HDAC family members 
(Galli et al., 2010; Knipstein and Gore, 2011; Younes et al., 
2011; Santo et al., 2012; Evens et al., 2016). In this context, 
targeting HDAC6 was associated to the upregulation of CD20 
and consequent enhanced efficacy of anti-CD20 monoclonal 
antibody therapy (Bobrowicz et al., 2017). Also, tucidinostat 
(CS055/chidamide), the first oral subtype-selective HDACi, was 
approved for the treatment of refractory/relapsed PTCL by the 
China Food and Drug Administration. This compound inhibits 
HDAC1, HDAC2, HDAC3, and HDAC10, and has entered a 
phase II clinical trial as single-agent treatment for patients with 
R/R B-NHL (NCT03245905) based on preliminary evidences of 
clinical activity in DLBCL (Yang et al., 2018).
Another approach to maximize efficacy with manageable 
toxicity consists in developing dual inhibitors. In this field, 
CUDC-907, a novel first-in-class oral small molecule inhibitor 
of both HDAC (class I and II) and PI3K (class Iα, β, and δ), 
has demonstrated excellent levels of activity (55% ORR) and 
tolerability in DLBCL patients in a phase IA clinical trial (Younes 
et al., 2016). In a second phase IB trial, the drug has been tested 
in patients with R/R DLBCL and showed a response rate of 
37%, with a higher effect in MYC-altered versus MYC-unaltered 
patients (Oki et al., 2017). As a result of these encouraging 
initial data, this agent is currently being evaluated in a phase 
II study including DLBCL patients, and also in a phase I trial 
involving pediatric patients with lymphomas (NCT02674750 
and NCT02909777).
TARGETING READER EPIGENETIC 
ENZYMES
BET Inhibitors
Among the post-translational modifiers with ability to orchestrate 
chromatin organization, bromodomain (BD)-containing proteins 
are readers of Ac-K residues at the N-terminal histone tails. They 
act as scaffolds that enable histone attachment to the chromatin 
and form active multi-protein transcription complexes, thereby 
modulating chromatin dynamics and ultimately diversifying 
gene expression (Filippakopoulos et al., 2012; Chaidos et al., 
2015; Smith and Zhou, 2016). This family of proteins contains 46 
members, comprising nuclear proteins with HAT or HMT activity, 
chromatin remodelers, helicases, transcription co-activators, and 
mediators or scaffold proteins. They are subdivided into eight 
subfamilies (I to VIII), based on their structure and sequence 
similarities. Subfamily II is the most studied one and includes 
the bromodomain-containing proteins mBRDT, BRD2, BRD3, 
and BRD4 (Padmanabhan et al., 2016). Besides the presence 
of two bromodomains (BD1 and BD2) that allow acetylated 
chromatin recognition, these proteins harbor an extra-terminal 
domain, which is responsible for protein–protein interactions. 
This bromodomain and extra-terminal (BET) subfamily has thus 
the capacity to act as protein adaptors facilitating the recruitment 
of chromatin remodelers and transcription factors for further 
initiation and elongation of transcription (Delmore et al., 2011; 
Chaidos et al., 2015; Padmanabhan et al., 2016). Several reports 
have highlighted the importance of the BET proteins action 
over DNA enhancers for the regulation of certain oncogenes 
expression (Lovén et al., 2013). Altogether, these studies make 
BET proteins attractive therapeutic targets in cancer.
As interfering with this family of proteins may serve as a 
strategy to address transcription irrespective of the presence 
of epigenetic mutations, BET proteins inhibitors have been a 
significant area of focus in the last decade, in cancer but also in 
inflammation, fibrosis, and heart diseases (Vakoc, 2015). Drug 
developmental studies have paid special attention to the Ac-K 
binding sites in the bromodomains, as these deep hydrophobic 
pockets with conserved asparagine and/or aspartate residues 
make BET proteins highly druggable (Cox et al., 2016). Indeed, 
the most common drug targeting approach in this family has 
been the development of small molecules that could block the 
lysine-binding pocket and disrupt the interactions between BDs 
and the Ac-K on chromatins (Smith and Zhou, 2016).
In 2005, a first bromodomain inhibitor developed by the Zhou 
laboratory, namely NP1, has the ability to target the BD of the 
P300/CBP-associated factor transcriptional coactivator (Zeng 
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et al., 2005). This step was followed by the discovery in 2006 of 
MS7972, a weakly binding fragment specific for CREBBP-BD, 
hindering its binding to acetylated p53 (Sachchidanand et al., 
2006). Among BET proteins, the first target considered to be 
druggable was BRD4, as a pioneering RNAi base unveiled its 
critical role in the maintenance of AML. In this study, authors 
found that BRD4-dependent transcriptional activity could be 
efficiently targeted by the pan-BET thieno-triazolo-1,4-diazepine 
(+)-JQ1 (Filippakopoulos et al., 2010; Zuber et al., 2011). This 
class of diazepine-based small molecule inhibitors, which also 
includes the benzodiazepine I-BET151 (GSK1210151A) (Dawson 
et al., 2011) and I-BET762 (GSK525762) (Mirguet et al., 2013) 
(NCT01943851), utilizes the methyltriazolo-diazepine ring 
system as the acetyl-mimetic. Further studies demonstrated that 
inhibition of BRD4 by (+)-JQ1 unveiled the MYC downregulation 
and, consequently, a genome-wide inhibition of its target genes 
(Filippakopoulos et al., 2010; Delmore et al., 2011). These results 
underlined significant preclinical activity of this inhibitor in 
MYC-driven B-NHL, including the aggressive, so-called “double 
hit” lymphoma (DHL), characterized by simultaneous oncogenic 
activation of MYC and/or BCL2/BCL6 (Johnson-Farley et al., 
2015). Accordingly, (+)-JQ1 could increase survival of mice 
xenografted with MYC-driven lymphoma, including those 
ones bearing either TP53 deletions or intrinsic resistant to the 
topoisomerase II inhibitor etoposide (Hogg et al., 2016).
These promising results from (+)-JQ1 encouraged the 
development of BET inhibitors with similar chemical structure, 
including the BRD4 inhibitor CPI203 characterized by a 
higher bioavailability profile in mice (Normant et al., 2012; 
King et al., 2013). This agent displayed remarkable efficacy in 
different preclinical models of B-NHL, either as single agent 
or in combination with the BCL-2 antagonist venetoclax in 
DHLs (Esteve-Arenys et al., 2018), in DLBCL-ABC (Ceribelli 
et al., 2014) and in both ABC and GCB subtypes of DLBCL in 
combination with blockade of the CXCR4 chemokine receptor 
(Recasens-zorzo et al., 2018). In these studies, BRD4i activity 
was mainly related to the blockade of MYC transcriptional 
program. This is of special interest, as despite its central role 
in multiple hematological malignancies, including various 
subtypes of B-NHL, direct targeting of MYC was considered 
impossible until the demonstration that BET inhibition 
could regulate MYC activity in varied contexts, thanks to 
alleviation of BRD4 occupancy on MYC super-enhancers. 
Importantly, beside MYC, different anti-apoptotic proteins like 
BCL-2 and MCL-1 are also downregulated, either by direct 
transcription repression or as a downstream consequence of 
BRD4 antagonism (Vakoc, 2015). Unlike the expected general 
effects of BET inhibition in the elongation of transcription of 
several genes, changes in the expression of only a small subset 
of genes was observed in cultures and/or animals receiving 
this therapy, suggesting that bromodomain inhibitors might 
be suitable modulators of certain disease-associated genes. As 
an illustration, high levels of BRD4 co-localize in CLL cells 
with super-enhancer sites of genes and microRNAs belonging 
to the BCR-mediated signaling pathway with possible tumor-
initiating activity, including miR-21, miR-15, TCL1, IL21R, 
and IL4R. Accordingly, in a mouse model of CLL, exposure 
to the BET inhibitor PLX51107 promoted an expression 
downmodulation of several tumor-associated genes, followed 
by consistent reduction in tumor burden (Ozer et al., 2018).
According to these promising results, in the last years 
a number of clinical leads have entered into trials for the 
treatment of hematological patients. Nevertheless, several side 
effects have been reported including some bone marrow and 
gastrointestinal toxicity that has forced to dose discontinuation 
or reduction. Nowadays, 18 BET inhibitors are being assessed 
in clinical trials either as single agents or in combination with 
other compounds (Table 4). While the data from various solid 
tumor trials look mitigated, several BETis including birabresib 
(OTX015, MK-8628), molibresib (GSK525762), RO6870810/
TEN-010, and mivebresib (ABBV-075) have demonstrated 
remarkable clinical efficacy in myeloproliferative disorders, 
while other small molecule inhibitors such as PFI-1, BI-894999, 
FT-1101, INCB-54329, and CPI0610, a pharmacological 
derivative of CPI203, are currently undergoing human clinical 
trials in these patients (Table 3). Among these different 
molecules, molibresib has demonstrated an 18.5% ORR in 
various subtypes of NHLs including a CR in a DLBCL case 
(Dickinson et al., 2018). CPI0610 has also been evaluated in 
a phase I clinical trial (NCT01949883) in 64 R/R FL, DLBCL, 
or HL patients, showing leading to a complete remission in 
one FL case and in four DLBCL patients (Blum et al., 2018). In 
addition, the compound INCB057643 is currently being tested 
in a third phase I trial involving lymphoma patients, including 
some FL and DLBCL cases. In this evaluation trial, a CR has 
been achieved in one FL case whereas in two other patients, 
the disease has been stabilized (Forero-Torres et al., 2017). In 
the dose-escalation, open-label, phase I study with OTX015, 
TABLE 4 | Drug combinations with non-approved epigenetic agents in B-NHL.
Epigenetic drug 
class
Drug Agent used in 
combination
Trial identifier
HDAC inhibitor CUDC-907 Rituximab, venetoclax, 
and bendamustine
NCT01742988
Entinostat Isotretinoin NCT00098891
Molibresib NCT03925428
Mocetinostat Azacitidine NCT00543582
EZH2 inhibitor Tazemetostat Fluconazole, 
omeprazole, and 
repaglinide
NCT03028103
Atezolizumab and 
obinutuzumab
NCT02220842
Prednisolone NCT01897571
PF 06821497 SOC NCT03460977
BET inhibitor Molibresib Entinostat NCT03925428
RO6870810 Venetoclax and 
rituximab
NCT03255096
INCB057643 Gemcitabine, 
paclitaxel, rucaparib, 
abiraterone, ruxolitinib, 
and azacitidine
NCT02711137
FT-1101 Azacitidine NCT02543879
Source: https://clinicaltrials.gov/.
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a 47% complete remission was reported in 17 DLBCL cases; 
however, objective responses were seen in only three DLBCL 
patients and clinical activity in other six B-NHL patients 
(NCT01713582) (Amorim et al., 2016). More recently, the BETis 
molibresib, CC-90010, and INCB054329 are being challenged 
in clinical trials including various hematological malignancies 
(NCT02431260, NCT01943851, and NCT03220347), but no 
data have been released so far.
Although at the moment most of the tested compounds aimed 
at inhibiting BET bromodomains are pan-BET inhibitors, many 
efforts are being focused in targeting BET proteins in a more 
specific and novel way. These new approaches include ABBV-744 
(which targets bromodomain-containing protein II) (Sheppard 
et al., 2018), the bivalent BET inhibitors AZD5153 and MT1 (a 
JQ1-derived BETi) (Rhyasen et al., 2016; Tanaka et al., 2016), 
and the so-called BET-PROTACs (QCA570, dBET6, BETd-260, 
and ARV-771) that drive BET proteins to their degradation by 
proteolysis-targeted chimera (Raina et al., 2016; Winter et al., 
2017; Qin et al., 2018 ). These molecules have shown both to 
promote apoptosis in MCL-derived cells resistant to the first-
in-class Bruton’s kinase (BTK) inhibitor ibrutinib as well as to 
increase survival compared to OTX015-treated MCL xenografts 
(Sun et al., 2018). Although promising results have been reported 
for this new generation of BET-targeting agents in preclinical 
FIGURE 4 | Epigenetic-targeted effects on immuno-oncology mechanisms. In lymphoma B cells, DNMT, HDAC, and BET inhibitors (DNMTi, HDACi, BETi) regulate 
the expression of MHC class I and PD-1 ligands (PD-L1 and PD-L2). In effector T cells, DNMTi also upregulates the expression of PD-1 and CTLA-4, which leads to 
T-cell exhaustion. The effects of HDACi on FoxP3 decrease the infiltration of regulatory T cells into the tumor. Lastly, EZH2i decreases the regulatory and increases 
effector T-cell population in the microenvironment.
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FIGURE 5 | Different strategies for combining drugs targeting epigenetic regulators in B-cell lymphoma. (A) Epigenetic drugs can be used to overcome (left axis) or 
to circumvent (right axis) malignant B-cell resistance to targeted agents or to standard chemotherapeutic regimens. (B) Pre-exposure of tumor cells to epigenetic 
drugs induces profound modifications of cell transcriptional profile, thus priming them to the cytotoxic effect of chemotherapeutic and targeted agents.
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studies, their therapeutic window when moving to clinical trials 
has still to be evaluated.
Non-BET Bromodomain-Containing 
Proteins: the Histone Acetyltransferase 
CREB-Binding Protein (CBP)
As previously mentioned, chromatin modifications can regulate 
several important features of cell function. Among these 
modifications, histone lysine acetylation is generally associated 
with activation of gene expression (Shahbazian and Grunstein, 
2007). HAT enzymes can deposit acetyl marks on histones and 
modify chromatin structure. Such marks are also recognized by 
bromodomains, thus adding a second level of regulation of the 
transcription process (Kouzarides, 2007). The transcriptional 
co-activators CBP/p300 are highly homologous, multifunctional 
proteins that encode a single bromodomain each and possess 
HAT activity (Chen and Li, 2011; Delvecchio et al., 2013). CBP/
p300 act as transcriptional co-factors, involved in the regulation 
of several biological processes (Dancy and Cole, 2015). Animal 
studies have shown that CBP and p300 are required for the 
generation and activity of normal hematopoietic stem cells 
as well as for adult hematopoietic stem cell maintenance and 
function (Chan et al., 2011; Rebel et al., 2002). Consequently, 
CBP ablation has a direct impact on the quiescence, apoptosis, 
and self-renewal of adult hematopoietic stem cells (Chan et al., 
2011) and CBP/p300 have a tumor suppressor role in mice 
models (Kung et al., 2000; Kang-Decker et al., 2004; Chan et al., 
2011). This role of CBP and p300 as tumor suppressors has 
been also observed in B-NHL, where its inactivating mutation 
is a common event in FL and DLBCL, providing a rationale for 
employing drugs with the capacity to modulate acetylation and 
deacetylation processes in these tumors (Cerchietti et al., 2010; 
Mullighan et al., 2011; Pasqualucci et al., 2011a).
CHROMATIN REMODELERS: SwI/SNF 
AND BRG1 AND ARID1
The SWItch/Sucrose Non-Fermentable (SWI/SNF) complex was 
initially discovered in yeast. It is composed by polypeptides associated 
with a subset of proteins codified by the SWI1, SWI2, SNF2, 
SWI3, SWI5, and SWI6 genes (Pazin and Kadonaga, 1997). This 
complex regulates gene transcription by altering DNA–nucleosome 
interactions at expenses of ATP consumption, thus facilitating or 
impeding the accession of the transcription machinery at concrete 
genomic regions (Workman and Kingston, 2002). Several studies 
have reported its capacity to repair nucleotide excisions and DNA 
double-strand breaks by homologous recombination (Chai et al., 
2005). The mammalian analog of the SWI/SNF complex (mSWI/
SNF) is the BRG1-Associated Factors (BAF) complex. It comprised 
approximately 11 subunits encoded by 19 distinct genes assembled 
in different combinations according to its specific molecular 
mechanism of action, and in a concrete genomic region. Two of the 
BAF components are the human Brahma (hBRM, also SMARCA2) 
and the Brahma-related gene 1 (BRG1, also SMARCA4). These 
proteins are ATPase subunits (Khavari et al., 1993) and either one 
or the other constitute the core component of the BAF complex. 
They contain BDs within their structure that recognize and contact 
acetyl groups present in histone proteins (Wang et al., 1996). 
Although they share similarities in their domain composition, 
they interact with different families of transcription factors what 
confers to them specific functions in the BAF complex (Kadam and 
Emerson, 2003).
BRG1 has been reported to be the most frequently mutated protein 
of the BAF complex in cancer. Classically, it has been described as a 
tumor suppressor gene as inactivating mutations of its protein have 
been found in numerous solid tumors like breast, lung, gastric, 
bladder, colon, ovarian cancers, and melanomas (Atlas et al., 2012; 
Hodis et al., 2012; Jelinic et al., 2014), but also in determined B-NHL 
subtype like DLBCL and MCL (Cuadros et al., 2017). Concretely, 
these loss-of-function mutations lead to the upregulation of the 
pro-survival gene BCL2L1 in MCL, conferring to this malignancy 
primary resistance to treatment or eventually relapse after dual 
exposure to ibutrinib and venetoclax (Agarwal et al., 2019). Other 
studies described BRG1 as a potent oncogene, since its function was 
required for AML progression in mice, through its binding to MYC 
enhancer region and consequent aberrant expression of this second 
oncogene (Shi et al., 2013; Buscarlet et al., 2014).
Beside BRG1, several BRG-/BRM-associated factors (BAF 
subunits) participate in tumoral progression. Two of these subunits, 
namely the AT-Rich Interaction Domain 1A (ARID1A/BAF250A) 
and its homologous ARID1B/BAF250B, contain domains capable 
of recognizing and binding to AT-enriched genomic regions and 
C terminus region, stimulating the activation of transcription in a 
glucocorticoid receptor-dependent manner. The presence of each 
of them in the complex is mutually exclusive, suggesting specific 
roles at concrete genomic regions (Wang et al., 2004).
Mutations that truncate the ARID1A sequence and promote 
its degradation have been widely characterized in endometrial 
carcinoma (Kandoth et al., 2013), colon cancer (Atlas et al., 
2012), stomach cancer (Wang et al., 2011), bladder cancer (Gui 
et al., 2011), neuroblastoma (Sausen et al., 2013), and pancreatic 
or hepatocellular carcinoma (Biankin et al., 2012; Fujimoto 
et al., 2012), evidencing the role of this protein in preventing 
tumoral progression. Similar to the mutations reported for 
ARID1A, truncating mutations have also been identified for 
ARID1B although in a lesser frequency and most of them 
associated with neurodevelopmental disorders (Santen et al., 2012) 
or neuroblastomas (Lee et al., 2017). ARID1B knockdown has 
been reported to destabilize the SWI/SNF complex and inhibit 
cell proliferation in both ARID1A-mutant cancer cell lines and 
primary tumor cells, suggesting that this protein could constitute 
an interesting therapeutic target for the treatment of ARID1A-
mutant tumors (Helming et al., 2014).
INDIRECT INHIBITION OF EPIGENETIC 
DYSREGULATION BY IDH INHIBITORS
The enzyme isocitrate dehydrogenase (IDH) catalyzes the 
conversion of isocitrate into α-ketoglutarate (α-KG) by oxidative 
decarboxylation using NADP+ as a cofactor. The IDH1 isomer 
is located in the cytosol and the peroxisomes, whereas IDH2 is 
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found in the mitochondria. IDH enzymes play an important role 
in the tricarboxylic (TCA) or Krebs’ cycle, but are also related with 
other cellular functions such as the regulation of redox balance 
(Dang et al., 2016; Dang and Su, 2017). Mutations in IDH genes are 
most commonly found in the R132 codon of IDH1 and the R172 
and R140 codons of IDH2, which correspond to evolutionarily 
conserved residues in the enzyme active site which is critical 
for substrate binding. Mutant forms of IDH have much lower 
catalytic activity and are associated with metabolic alterations. 
More importantly, mutant IDH enzymes gain neomorphic 
activity as they convert α-KG into 2-hydroxyglutarate (2-HG). 
Under homeostatic conditions, 2-HG is only produced by errors 
in catalysis and it is maintained at low levels due to the action of 
2-HG-hydroxigenases (2-HGHD). Unlike in bacteria and plants, 
2-HG has no known physiological function in mammals (Dang 
and Su, 2017). 2-HG is structurally similar to α-KG and acts as a 
competitive inhibitor, blocking the activity of α-KG-dependent 
dioxygenases. This group of enzymes includes the TET family 
of hydroxylases, which participate in DNA demethylation, and 
the JMJ domain-containing histone demethylases (Dang and Su, 
2017). The consequent aberrant hypermethylation of both DNA 
and histones has been associated to a blockade in differentiation 
in hematopoietic cells (Figueroa et al., 2010; Losman et al., 
2013), hepatocytes (Saha et al., 2014), and mesenchymal stem 
cells (Jin et al., 2015), among other cell types.
Homozygous missense mutations in both IDH1 or IDH2 
have been described in several cancer types, including glioma, 
cholangiocarcinoma, and hematological tumors, such as 
AML and MDS (Dang et al., 2016). Although infrequent, 
mutations have also been found in lymphoid malignancies like 
angioimmunoblastic T-cell lymphomas (Cairns et al., 2012) 
and acute lymphocytic leukemia, both in pediatric (Andersson 
et  al., 2011; Tang et al., 2012) and adult cases (Kang et al., 
2009; Abbas et al., 2010; Zhang et al., 2012). Dysregulation of 
the IDH pathway has also been reported in CLL, as leukemic 
B cells from these patients show overexpression of IDH1 and 
lower levels of IDH2 when compared to healthy B cells (Van 
Damme et al., 2016).
Two IDH inhibitors have been recently approved by the 
FDA for the treatment of R/R AML in adults. Enasidenib (AG-
221) targets IDH2 with R172S, R172K, and R140Q mutations, 
whereas ivosidenib (AG-120) targets IDH1 with susceptible 
mutations, such as R132H and R132C (Han et al., 2019). Other 
non-approved IDH inhibitors are currently in clinical trials 
involving patients with advanced hematological cancers. Among 
these molecules, AG-881 is a pan-inhibitor of both IDH1 and 
IDH2 that can penetrate the blood–brain barrier, while IDH305, 
FT-2102, and BAY-1436032 are IDH1-specific inhibitors (Dang 
et al., 2016; Montalban-Bravo and DiNardo, 2018). At the 
preclinical level, the pharmacological IDH2 inhibitor AGI-
6780 displayed synergistic cytotoxicity in MCL and BL cell 
lines in combination with the proteasome inhibitor carfilzomib, 
mediated by the blockade of tricarboxylic acid cycle and the 
decrease in ATP levels, as a consequence of enhanced IDH2 
enzymatic inhibition (Bergaggio et al., 2019). Thus, although 
activating mutations of IDH genes are rare in B-NHL, there may 
be some room to evaluate, alone or in combination with standard 
chemotherapy, some of the molecules exhibiting clinical activity 
in non-lymphoid patients.
COMBINATION INvOLvING EPIGENETIC-
TARGETING APPROACHES
Concomitant Targeting of Different 
Epigenetic Modulators
In recent years, thanks to the many works directed to characterize 
and get a better understanding of the human epigenome, it 
came out that more than 50% of the human cancers account for 
aberrant changes in chromatin organization at certain genomic 
regions, as a consequence of mutations in enzymes involved in 
the regulation of chromatin structure (You and Jones, 2012; The 
Cancer Genome Atlas Research Network, 2013). Changes in the 
activity of these chromatin modifiers can lead not only to the 
initiation of a tumor formation process but also to its progression, 
metastasis, development of drug resistances, and further relapse 
and/or escape from immune surveillance (Jones et al., 2016). 
Therapeutic modulation of such alterations can be achieved with 
chemical compounds that broadly affect the structure of the 
DNA such as DNMTis, histone HDACis, or BETis (Figure  4). 
While single-agent clinical trials with these compounds have 
been conducted with some success in MDS or R/R AML 
patients receiving azacitidine (Scott, 2016; Schuh et al., 2017) 
or in R/R FL, MZL, and MCL patients treated with vorinostat 
(Kirschbaum et al., 2011; Ogura et al., 2014), the association of 
these agents with other compounds has also been tested. As an 
example, the combinatorial treatment with vorinostat and the 
sirtuin inhibitor niacinamide was evaluated in R/R NHL and HL 
cases (NCT00691210) (Amengual et al., 2013), but it achieved a 
modest efficiency with an ORR below 50% (Olsen et al., 2007). 
Other examples include the combination of panobinostat with 
decitabine which displayed synergistic caspase-dependent cell 
death in DLBCL cells (Kalac et al., 2011) or the combination of 
romidepsin with the antimetabolite pralatrexate for the treatment 
of relapsed PTCL (Amengual et al., 2018).
A different therapeutic approach consists in targeting 
specifically certain chromatin regulatory proteins to achieve a 
more restricted effect in the transcription of a concrete subset of 
genes. Promising examples are the inhibition of the DOT1-like 
(DOT1L) histone H3K79 methyltransferase with pinometostat 
(EPZ-5676) in adults with MLL/KMT2A-driven leukemia 
(NCT02141828) (Stein et al., 2018) or inhibition of histone 
H3K4 and K9 demethylation by the lysine-specific demethylase 1 
(LSD1) inhibitor seclidemstat, currently being assessed in clinical 
trials to treat refractory Ewing sarcomas (NCT03600649).
Combinations with chemical compounds that broadly 
affect an epigenetic mark and a specific inhibitor of a 
chromatin-modifying enzyme, such as the EZH2 inhibitor 
GSK126 and romidepsin, have also been assessed in 
preclinical studies with DLBCL-GCB cell lines, leading 
to synergistic tumor growth inhibition effects in mice 
(Lue et al., 2019). Another example of the strategies currently 
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evaluated in clinical studies is the concomitant treatment 
of drug-resistant MM with panobinostat and bortezomib 
(NCT01083602) (Richardson et al., 2016).
Finally, and in concordance with the concept that acquired 
resistance to chemotherapy is tightly linked to changes in 
chromatin structure, many efforts have been made in identifying 
combinational strategies associating different types of cytotoxic 
drugs to small molecule regulators of chromatin modifiers. As an 
example, the dinitroazetidine derivative RRx-001 administered in 
combination with radiation, chemotherapy, or immunotherapies 
promotes the generation of reactive oxygen and nitrogen species, 
leading to the oxidation of the cysteines present at the catalytic 
sites of DNMTs and HDACs. This phenomenon entrains 
the inhibition in DNMT and HDAC enzymatic activities, 
with subsequent alterations in the chromatin structure. The 
therapeutic benefits of this compound have been assessed in 
phase II clinical trials both as a radio- and chemo-sensitizer, as 
well as a way to prone tumor response to conventional therapies 
(NCT02215512, NCT02452970, NCT02096341, NCT02871843) 
(Oronsky et al., 2017; Zhao et al., 2017).
Combination of Epigenetic Drugs with 
Other Classes of Anti-Tumoral Drugs
The use of epigenetic agents combined with other anti-tumoral 
drugs may represent the future of epigenetic-targeted therapies 
(Figure 5). The rationale of such combinations would be, on the 
one hand, to benefit from the transcriptional effects of targeting 
epigenome. Indeed, growing evidences are showing that 
epigenetic therapy, using DNMTi or HDACi, in combination 
with conventional therapy or immunotherapy, might be an 
up-and-coming step toward the development of new and efficient 
cancer treatment strategies (Brahmer et al., 2012; Sharma and 
Allison 2015; Topalian et al., 2015; Issa et al., 2017). Accordingly, 
the acquired capacity of tumors to resist chemotherapy is related 
with changes in the cancer cell’s epigenome, which might affect 
directly the cell cycle and/or some key apoptosis regulators 
(Fodale et al., 2011).
In a phase I study, Clozel and collaborators proposed a new 
approach to beaten chemotherapy resistance in DLBCL patients. 
The authors demonstrated a high rate of complete remission 
when a 5-day exposure to azacitidine followed by treatment with 
R-CHOP was employed. Mechanistically, the treatment leads 
to the demethylation of the chemoresistance-associated gene 
SMAD1 and subsequent chemosensitization (Clozel et al., 2013). 
Based on these results, an ongoing phase I study using azacitidine 
combined with R-CHOP in therapy-naive DLBCL, grade 3B FL, 
or transformed FL patients is showing promising preliminary 
results (NCT02343536). Finally, the safety and tolerability of 
adding oral azacitidine to R-ICE therapy is being evaluated in 
R/R DLBCL patients (NCT03450343).
Regarding HDACi, in vitro studies have demonstrated that 
this class of agents can synergize with chemotherapy. Globally, 
these trials have had mixed heterogeneous results. Among the 
potently successful studies, in indolent B-NHL the vorinostat/
rituximab combination exhibited a nice activity with an 
acceptable safety profile and durable responses (Chen  et al., 
2015). Ageberg and collaborators also showed that valproic 
acid sensitizes to CHOP and enhances the CHOP ability to 
induce apoptosis in DLBCL cell lines (Ageberg et al., 2013). 
Subsequently, it has been shown in a small set of DLBCL 
patients that the administration of valproate before R-CHOP 
treatment upregulated the CD20 levels and increased the 
efficacy of anti-CD20-based therapy (Damm et al., 2015). 
Recently, the VALFRID phase I trial (NCT01622439) showed 
that valproate when added to standard R-CHOP therapy 
is secure, tolerable, and increases OS in DLBCL patients 
(Drott et al., 2018). The efficacy of vorinostat combined with 
cyclophosphamide, etoposide, and prednisone (R-CVEP) was 
evaluated in aged patients with R/R DLBCL (NCT00667615); 
however, the R-CVEP association did not reach the criteria 
for cohort expansion (Straus et al., 2015). Similarly, the 
combination of vorinostat with R-CHOP was evaluated in the 
SWOG S0806 phase I/II trial (NCT00972478) without success 
in DLBCL patients (Persky et al., 2018). Panobinostat was 
tested in combination with conventional therapy and although 
the data from the clinical trial NCT01238692 suggested that as 
a single agent this drug induces a durable response in a subset 
of R/R DLBCL patients, its combination with rituximab did not 
improve the response rate (Assouline et al., 2016). Similarly, 
Barnes and collaborators observed that this combination was 
effective in a minority of DLBCL patients heavily pretreated 
(NTC01282476) (Barnes et al., 2018). The combination with 
immunomodulatory drug (IMiD) lenalidomide was assessed in 
a phase I/II clinical trial in patients with R/R HL (NCT01460940); 
however, the combination was not advantageous over single-
agent treatment and raised relevant concerns regarding the 
toxicity (Maly et al., 2017). Finally, preclinical data have shown 
that belinostat exhibits synergistic cytotoxic activity in DLBCL 
cell lines when associated to the microtubule-interfering drug 
vincristine, mediated by the prevention of cell polyploidy 
(Havas et al., 2016).
Regarding EZH2 inhibitors, combinatorial treatments with 
tazemetostat and the anti-programmed death-ligand 1 (PDL1) 
antibody atezolizumab (NCT02220842), prednisone alone, or 
combined with other components of CHOP regimen are currently 
being evaluated in patients with refractory DLBCL (NCT02889523) 
(Gulati et al., 2018). Moreover, combinations with EZH2 inhibitors 
and inhibitors of the BCR signaling cascade such as ibrutinib, the 
spleen tyrosine kinase (SYK) inhibitor tamatinib, the mammalian 
target of rapamycin (mTOR) inhibitor everolimus, or MAPK 
inhibitor have also been challenged in pre-clinical models of 
DLBCL (Brach et al., 2017; Lue et al., 2017). Other therapeutic 
strategies currently assessed in pre-clinical studies for the 
treatment of MM consist in combining the inhibitor tazemetostat 
with IMiDs such as lenalidomide or pomalidomide (Dang et al., 
2016), glucocorticoid receptor agonists (dexamethasone or 
prednisolone), proteasome inhibitors (bortezomib or ixazomib) 
(Drew et al., 2017), or HDACis (Issa et al., 2017).
Finally, in combination with the CDK4/6 inhibitor palbocilib, 
the BETi JQ1 has shown synergistic activity in MCL in vitro and in 
vivo (Sun et al., 2015). Another member of the CDK family, CDK9, 
is a core component of the assembly of the positive transcription 
elongation factor complex (P-TEFb), which is recruiting by BRD4. 
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In relation with this, the BETi BI-894999 shows profound synergy 
with CDK9 inhibitors alvocidib and LDC000067 in both in vitro 
and in vivo models of hematological malignancies (Doroshow et al., 
2017). Among other promising combinations, CPI203 combined 
with the proteasome inhibitor bortezomib or with lenalidomide 
was particularly efficient in aggressive bortezomib-resistant MCL 
tumors (Moros et al., 2014), and GS-5829 synergistically interacted 
with venetoclax or with BCR-interfering agents in preclinical models 
of DLBCL, MCL, and/or CLL (Bates et al., 2016; Kim et al., 2017).
CONCLUSIONS
Besides the well-known genomic changes, several epigenetic 
modifications that result in an altered chromatin state and 
alterations in the DNA methylation status have been described in 
lymphoma cells. In general, these alterations favor the malignant 
transformation and/or tumor progression. Among the mechanisms 
that may apply to several lymphoma entities, epigenetic activation 
of suppressors of lineage fidelity leads to downregulation of lineage-
specific genes, while additional silencing of essential transcription 
factors through H3K27 trimethylation avoids the restoration of 
the cell type characteristic expression program. Therefore, there is 
undoubtedly an important clinical role for epigenetic drugs across 
the spectrum of lymphoid malignancies, including B-NHL.
In the last decade, the progresses in the awareness of epigenetic 
changes in lymphoma cells have paved the way for targeted therapy 
alternatives employing epigenetic drugs. Treatment approaches such 
as HDAC inhibition or DNMT blockade have shown remarkable 
activity in specific subsets of lymphoma patients who remained 
unresponsive to or relapsed after standard therapy. These drugs have 
already been added into routine use for patients with a particular 
lymphoma/leukemia subtype and are the most broadly studied now. 
However, the identification of biomarkers of clinical sensitivity/
resistance to these agents is still needed in order to better identify 
those lymphoma patients suitable for treatment with these drugs, 
and for the design of rationally based targeted combination therapies. 
Although several epigenetic drugs can be successfully combined 
with standard chemotherapy, allowing to decrease the chemotherapy 
doses and to limit toxicities and adverse effects, co-administration of 
two epigenetic modulators like DNA hypomethylating agents and 
HDAC inhibitors, for example, can also show synergistic molecular 
effects, resulting in increased antitumor activity.
In the light of the large number of drugs currently in clinical 
development in B-NHL patients, selection of the most relevant 
targeted therapies will be extremely important to move the field 
ahead. Epigenetic drugs with more specific targets, such as EZH2 
inhibitors or BRD4 inhibitors, but also the newer epigenetic 
agents like PRMT5 and IDH inhibitors, are also of great interest, 
as demonstrated by a particularly rapid translation from bench to 
bedside within the past 5 years.
Despite these considerable advances in epigenetic drug therapy 
in B-cell lymphoma, there is still some way to go before reaching 
a complete overview of the complex landscape of the epigenetic 
modifications occurring during the lymphomagenesis, and much 
work is still to be done to improve the rationale use of epigenetic 
drugs in lymphoma patients. According to the promising reports 
from several trials involving the newest agents and the most 
innovative drug combinations in B-NHL patients with relapse 
disease, it seems that we are entering a very exciting era for the 
field of epigenetics in lymphoma.
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